{"id":2027,"date":"2026-08-07T11:22:23","date_gmt":"2026-08-07T11:22:23","guid":{"rendered":"https:\/\/valutednews.com\/?p=2027"},"modified":"2026-08-07T11:22:23","modified_gmt":"2026-08-07T11:22:23","slug":"advocacy-groupmedicare-decision-helped-put-off-talks-on-abbvie-drug-price","status":"publish","type":"post","link":"https:\/\/valutednews.com\/?p=2027","title":{"rendered":"Advocacy group:Medicare decision helped put off talks on AbbVie drug price"},"content":{"rendered":"
\"Advocacy<\/div>

<\/p>\n

\n

Ed\u2019s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter<\/a> and the afternoon Pharmalot newsletter<\/a>.<\/p>\n<\/div>\n

\n

A little-noticed policy shift by Medicare caused a seven-year delay in choosing a costly AbbVie medicine for price negotiations, a move likely to hurt taxpayers, according to an analysis by a consumer advocacy group.<\/p>\n

The change occurred as the Centers for Medicare and Medicaid Services readied a new round of talks with drugmakers over prices that the agency would pay for a limited number of medicines. The process was created by the Inflation Reduction Act, which became law in 2022 in response to the rising cost of prescription drugs.<\/p>\n

\n
\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n<\/p><\/div>\n

\t\t\t\"STAT+\"\/<\/p>\n

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a>
\n\t\t\t\t<\/span><\/p>\n

This article is exclusive to STAT+ subscribers<\/h2>\n

Unlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/h3>\n

Already have an account? Log in<\/a><\/p>\n

\n
\n\t\t\t\t\t\t